Therefore, the study treatment would be considered successful if the lower limit of a two-sided 95% confidence interval of median PFS estimated on a Kaplan-Meier curve was greater than 2 months. With a sample size of 37, there would be 90% power to detect an improvement in median PFS from 2 to 3.5 months with a two-sided alpha of 5%.
Thirteen patients were enrolled. Twelve patients completed at least one cycle and were evaluable for efficacy. The median age was 65 (range: 55-76) and patients had received a median of six prior lines of therapy. Baseline characteristics are summarized in Table S1 . The median time between patients becoming refractory to a CFZ 20/27
containing regimen and the present study was 3.12 (0.7-13.63) months. Patients completed a median of four (1-16) cycles of treatment on study. In all but one patient the reason for treatment discontinuation was progression of disease. One patient came off study per investigator discretion due to grade 4 elevated gamma-glutamyl transpeptidase that was possibly related to carfilzomib. After enrollment of 13 patients, the study was closed as accrual became challenging due to widespread use of CFZ doses greater than 20/27.
With CFZ 20/56 and only premedication dosing of dexamethasone, of the 12 patients evaluable for efficacy, the ORR was 33%, CBR was 50%, and median PFS was 3.2 months. These results compare favorably with the outcomes patients had previously attained when they were CFZ naïve and treated with CFZ 20/27 that is, ORR, CBR, and PFS of 33%, 42%, and 3.7 months, respectively (Table S2) . Figure S1 .
All AEs considered to be related to CFZ 20/56 are listed in Table S3 . The most common AEs of any grade were thrombocytopenia (54%), anemia (38%), acute kidney injury (38%), hypertension (38%), headache (31%), neutropenia (23%), and dyspnea (23%).
In this phase 2 study, CFZ 20/56 was well tolerated with grade 3 hypertension seen only in two patients (15%) and no patients developed clinically evident congestive heart failure, echocardiographic evi- Results from the relevant randomized phase 2 SWOG S1304 study comparing CFZ 20/56 vs 20/27 in patients with RRMM were recently presented. 6 Although patients who received CFZ 20/56 vs 20/27 had higher VGPR rates, there was no significant difference in PFS or OS. Crossover between low-dose and high-dose carfilzomib was allowed and a total of 16 patients crossed over due to disease progression. In contrast to our study which found that CFZ 20/56 was able to recapture responses in CFZ 20/27-refractory patients, no responses (MR or better) were noted among the 16 patients who crossed over from the CFZ 20/27 to 20/56 group. The difference in response seen to CFZ 20/56 in patients refractory to CFZ 20/27 in our study compared to the SWOG S1304 study is unclear, although time to dose-escalation could be considered a contributing factor. In the SWOG S1304 study, all patients were increased to CFZ 20/56 while progressing on CFZ 20/27 compared to our study in which most patients were refractory to carfilzomib in a previous line of therapy not immediately preceding study enrollment. However, time to dose-escalation does not likely fully account for the difference as 4 of 12 evaluable patients in our study were refractory to a carfilzomibcontaining regimen immediately prior to study entry, two of which achieved SD and two of which achieved MR on CFZ 20/56.
The major limitation of the current study is the changing land- 
